 Updated News | Study: New heart failure drug cuts death by 37 percent Catholic Online An experimental drug, called serelaxin from the Novartis AG drug group to treat hospitalized acute heart failure patients has reported remarkable success. The death rate was decreased by as much as 37 percent compared with a placebo and appeared to be ... Acute Heart Failure: Serelaxin Shines in Phase III Trial Novartis' heart failure drug faces hurdles despite upbeat PhIII results Serelaxin: Acute Heart Failure Drug Reduces Deaths By 37%, Study Shows |
